Subclinical inflammation and prothrombotic state in heart transplant recipients: Impact of cyclosporin microemulsion vs. tacrolimus

Transplantation

Volumn 82, Issue 6, 2006, Pages 763-770

  White, Michel ^a   Ross, Heather ^b   Haddad, Haissam ^c   LeBlanc, Marie Hélène ^d   Racine, Normand ^a   Pflugfelder, Peter ^e   Giannetti, Nadia ^f   Davies, Ross ^g   Azevedo, Eduardo ^h   Isaac, Debra ⁱ   Burton, Jeffrey ^j   Ferguson, Ralph ^k   Genest, Jacques ^f  

^a MONTREAL HEART INSTITUTE   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f ROYAL VICTORIA HOSPITAL   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

^h HEALTH SCIENCES CENTRE   (Canada)

ⁱ FOOTHILLS HOSPITAL   (Canada)

^j UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^k Astellas Pharma Canada Inc   (Canada)

more..

Author keywords

Calcineurin inhibitors; Cardiac transplantation; Dyslipidemia; Inflammation; Thrombosis

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; TACROLIMUS; URIC ACID; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; HEMOSTASIS; HUMAN; IMMUNOPROPHYLAXIS; INFLAMMATION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THROMBOSIS;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CYCLOSPORINE; DYSLIPIDEMIAS; EMULSIONS; HEART TRANSPLANTATION; HEMOSTASIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TACROLIMUS; THROMBOSIS;

EID: 33749125866     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000232286.22319.e0     Document Type: Article

References (54)

1. Bennett LE, Keck BM, Daily OP, et al. Worldwide thoracic organ transplantation: A report from the UNOS/ISHLT International registry for thoracic organ transplantation: In: Cecka and Terasaki, eds. Clinical Transplants 2000; 3: 31.
2. Gaudin PB, Rayburn BK, Hutchins GM, et al. Peritransplant injury to the myocardium associated with the development of accelerated arteriosclerosis in heart transplant recipients. Am J Surg Pathol 1994; 18: 338.
3. Hruban RH, Gao SZ, Baldwin WM III, Schroeder JS. Accelerated graft arteriosclerosis. In: Baumgartner WA, Reitz B, Kasper E, Theodore J, eds. Heart and Lung Transplantation. New York: WB Saunders Co., 2002: 387.
4. Pouteil-Noble C, Hemdawy A, Villar E, et al. Chronic renal failure and end-stage renal disease are associated with a high rate of mortality after heart transplantation. Transplant Proc 2005; 37: 1352.
5. Tuzcu EM, Kapadia SR, Sachar R, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005; 45: 1538.
6. Bieber CP, Hunt SA, Schwinn DA, et al. Complications in long-term survivors of cardiac transplantation. Transplant Proc 1981; 13: 207.
7. Valantine HA. Role of lipids in allograft vascular disease: A multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant 1995; 14: S234.
8. Kapadia SR, Nissen SE, Ziada KM, et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: A serial intravascular ultrasound study. J Am Coll Cardiol 2001; 38: 206.
9. Lee KW, Lip GYH, Tayebjee M, et al. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005; 105: 526.
10. Von Eyben FE, Mouritsen EA, Holm J, et al. Fibrinogen and other coronary risk factors. Metabolism 2005; 54: 165.
11. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005; 3: 1618.
12. Maccalum PK. Markers of hemostatis and systemic inflammation in heart disease and atherosclerosis in smokers. Proc Am Thorac Soc 2005; 2: 34.
13. Haverkate F. Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. Vasc Pharmacol 2002; 39: 109.
14. Hognestad A, Endresen K, Wergeland R, et al. Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol 2003; 42: 477.
15. Kutschka I, Pethig K, Harringer W, et al. Increased plasma homocysteine concentrations accelerate cardiac allograft vasculopathy. J Heart Lung Transplant 2004; 23: 1260.
16. White M, Haddad H, Leblanc MH, et al. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: The Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. J Heart Lung Transplant 2005; 24: 798.
17. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27(Suppl 2): S1.
18. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433.
19. Anguita M, Lopez-Rubio F, Arizon JM, et al. Repetitive nontreated episodes of grade 1b or 2 acute rejection impair long-term cardiac graft function. J Heart Lung Transplant 1995; 14: 452.
20. Cramer DV, Qian S, Harnaha J, et al. Accelerated graft arteriosclerosis is enhanced by sensitization of the recipient to donor lymphocytes. Transplant Proc 1989; 21: 3714.
21. Paramo JA, Beloqui O, Colina I, et al. Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects. J Thromb Haemost 2005; 3: 662.
22. Chan NN, Fuller JH, Rubens M, Colhoun HM. Von Willebrand factor type 1 diabetes: Its production and coronary artery calcification. Med Sci Monit 2003; 9: CR297.
23. Libby P, Ridker PM. Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. Am J Med 2004; 116: 9S.
24. Becker A, van Hinsbergh VW, Jager A, et al. Why is solube intercellular adhesion molecule-1 related to cardiovascular mortality? Eur J Clin Invest 2002; 32: 1.
25. Leu HB, Lin CP, Lin WT, et al. Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: The role of high-sensitivity C-reactive protein. Chest 2004; 126: 1032.
26. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45: 828.
27. Schaumberg DA, Glynn RJ, Jenkins AJ, et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 2005; 111: 2446.
28. Horan JT, Francis CW, Falsey AR, et al. Prothrombotic changes in haemostatic parameters and C-reactive protein in the elderly with winter acute respiratory tract infections. Thromb Haemost 2001; 85: 245.
29. Makin AJ, Blann AD, Chung NA, et al. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Eur Heart J 2004; 25: 371.
30. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387.
31. Kistorp C, Raymond I, Pedersen F, et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609.
32. Tanaka A, Shimada K, Sano T, et al. Multiple plaque rupture and C-reactive in acute myocardial infarction. J Am Coll Cardiol 2005; 45: 1594.
33. Di Napoli M, Schwaninger M, Cappelli R, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: A statement for health care professionals from the CRP Pooling Project members. Stroke 2005; 36: 1316.
34. van Dijk EJ, Prins ND, Vermeer SE, et al. C-reactive protein and cerebral small-vessel disease: The Rotterdam scan study. Circulation 2005; 112: 900.
35. Narins CR, Zareba W, Moss AJ, et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 2004; 164: 440.
36. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: Implications for future risk assessment: Results from a large cohort study in southern Germany. Circulation 2004; 109: 1349.
37. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105: 2595.
38. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002; 325: 1202.
39. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: Results of a meta-analysis. Neurology 2002; 59: 529.
40. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999; 159: 1077.
41. Buccianti G, Baragetti I, Bamonti F, et al. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 2004; 17: 405.
42. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol 2004; 15: Suppl 1: S77.
43. Moreno JM, Ruiz MC, Ruiz N, et al. Modulation factors of oxidative status in stable renal transplantation. Transplant Proc 2005; 37: 1428.
44. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14719 initially healthy American women. Circulation 2003; 107: 391.
45. Dzielak DJ. The immune system and hypertension. Hypertension 1992; 19: 36.
46. Widiana IG, Suwitra K. Relationship between creatinine clearance and plasma homocysteine levels in predialytic chronic renal failure patients. Acta Med Indones 2004; 36: 15.
47. Hauptman PJ, Davis SF, Miller L, Yeung AC. The role of nonimmune risk factors in the development and progression of graft atherosclerosis: Preliminary insights from a multicenter intravascular ultrasound transplant study. Multicenter Intravascular Ultrasound Transplant Study Group. J Heart Lung Transplant 1995; 14: 238.
48. Margreiter R, Pohanka E, Sparacino V, et al. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects. Transpl Int 2005; 18: 816.
49. Baid-Agrawal S, Delmonico FL, Tolkoff-Rubin NE, et al. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. Transplantation 2004; 77: 1199.
50. Kramer BK, Boger C, Kruger B, et al. Cardiovascular risk estimates and risk factors in renal transplant recipients. Transplant Proc 2005; 37: 1868.
51. Artz MA, Boots JMM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4: 937.
52. Laurés AS, Gomez E, Alvarez V, et al. Influence of anticalcineurinic therapy in plasma homocysteine levels of renal transplant recipients: A prospective study. Transplant Proc 2003; 35: 1739.
53. Potena L, Grigioni F, Magnani G, et al. Homocysteine-lowering therapy and early progression of transplant vasculopathy: A prospective, randomized, IVUS-based study. Am J Transplant 2005; 5: 2258.
54. Kapadia SR, Ziada KM, L'Allier PL, et al. Intravascular ultrasound imaging after cardiac transplantation: Advantage of multi-vessel imaging. J Heart Lung Transplant 2000; 19: 167.